Daily Stock Analysis, ACST, Acasti Pharma Inc, priceseries

Acasti Pharma Inc. Daily Stock Analysis
Stock Information
Open
1.25
Close
1.28
High
1.34
Low
1.25
Previous Close
1.26
Daily Price Gain
0.02
YTD High
1.75
YTD High Date
Jan 23, 2017
YTD Low
1.14
YTD Low Date
Mar 8, 2017
YTD Price Change
-0.01
YTD Gain
-0.78%
52 Week High
3.09
52 Week High Date
Sep 14, 2016
52 Week Low
1.11
52 Week Low Date
Dec 21, 2016
52 Week Price Change
-0.24
52 Week Gain
-15.79%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 17. 2015
4.50
Mar 2. 2015
5.00
9 Trading Days
11.13%
Link
LONG
Jun 19. 2015
3.50
Jun 22. 2015
3.70
1 Trading Days
5.71%
Link
LONG
May 23. 2016
1.35
May 26. 2016
1.43
3 Trading Days
5.93%
Link
LONG
Jul 14. 2016
1.56
Jul 15. 2016
1.68
1 Trading Days
7.37%
Link
LONG
Jan 23. 2017
1.45
Jan 24. 2017
1.52
1 Trading Days
5.17%
Link
LONG
Feb 17. 2017
1.33
Feb 21. 2017
1.41
1 Trading Days
5.64%
Link
Company Information
Stock Symbol
ACST
Exchange
NasdaqCM
Company URL
http://www.acastipharma.com
Company Phone
(450) 687-2262
CEO
Janelle D'Alvise
Headquarters
Quebec
Business Address
225 PROMENADE DU CENTROPOLIS, SUITE 200, LAVAL, CANADA H7T 3B3
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001444192
About

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of therapies for the treatment of various cardiometabolic disorders primarily abnormalities in blood lipids.

Description

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of therapies for the treatment of various cardiometabolic disorders primarily abnormalities in blood lipids. The company offers Onemia, a medical food product for the dietary management of omega-3 phospholipids deficiency, and related abnormal lipid profiles and cardiometabolic disorders. It also develops CaPre, a prescription drug candidate for the prevention and treatment of cardiometabolic disorders, such as hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma Inc. is a subsidiary of Neptune Technologies and Bioressources Inc.